Want to join the conversation?
$ENDP's 1Q16 revenue grew 35% versus 1Q15 due to Auxilium and Par acquisitions. US Branded revenue grew 8.5% due to higher net sales in Specialty Pharma and Branded Other. US Generic revenue grew 63.4% due to higher net sales in US Generics Base and Sterile Injectables. International Pharma revenue fell 2% due to foreign currency rate fluctuations.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?